Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
about
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agentsPharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosisUltra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapyVT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsAntifungal pharmacokinetics and pharmacodynamicsAnidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Interlaboratory reproducibility of Etest amphotericin B and caspofungin yeast susceptibility testing and comparison with the CLSI method.Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisRelationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.Tissue penetration of antifungal agents.Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.Echinocandin pharmacodynamics: review and clinical implications.Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.Uptake and efflux kinetics, and intracellular activity of voriconazole against Aspergillus fumigatus in human pulmonary epithelial cells: a new application for the prophylaxis and early treatment of invasive pulmonary aspergillosis.Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro.A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?
P2860
Q26827380-9F7CA9C4-307F-4F08-AFA3-7DDD823F708AQ34045435-F7EF4558-1F87-4521-85A0-5C3C5206DAF9Q34309527-53A5E497-9093-454B-A815-3E83832554A0Q34754956-CAF38947-B5EE-4491-859C-5FA429EEBAE1Q35168981-D0A9FA48-BC67-4311-93B0-D3DE762526D3Q35270270-81FDEBDA-F998-45E9-9B26-1D2486BEB856Q35270758-086D2683-71F7-479E-B931-71085DBC36BDQ35663841-1941E323-1F8A-4D8A-B6C3-399D3DD133A3Q35689202-D7D01D2B-4761-4212-AC73-721E89596135Q36118811-1E8CB44C-2E4B-4354-B5A4-277AC654C4CBQ36439102-539D7725-659D-4142-B6A4-AFC2F0EAD9EFQ37124182-86CAD4F8-4A68-4CDA-A4B9-4D865B8BB9D6Q37263435-AEDFEC6A-C273-4A90-84A1-3D37CF417E6FQ37335649-038648D9-EB71-44F1-8EEE-5B7ADBED256EQ37544911-1C7660E0-2537-4D1B-AE5D-C5E8BB22C585Q37558822-CEFA87E8-935B-4CDA-89B1-D232E8421556Q37718385-C295ACF7-7115-4FF6-B81B-015CA04829CBQ37720794-6497701D-49C9-41E9-B57C-72A78AA2DDA6Q38837353-67CB9CC0-D5E8-4196-8724-143353C74ED4Q38919690-AD36E821-8173-4086-9706-B81FD526E89BQ40247785-109C8F7A-F34B-46CF-8C31-E118B0258F50Q40396776-B00ECFA8-04B3-4E46-AFCD-BFE93EA84C8AQ48192025-EC8E4C8B-5144-4BF5-8402-39EAC5E339CAQ55479804-53260825-64DF-48D0-BF18-30E808AB5D7BQ57518528-0B21FC62-5E3A-47C9-8601-1BC0E421E454
P2860
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
@en
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
@nl
type
label
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
@en
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
@nl
prefLabel
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
@en
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
@nl
P1476
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
@en
P2093
G L Drusano
P304
P356
10.1111/J.1469-0691.2009.02913.X
P50
P577
2009-07-01T00:00:00Z